Similar articles for PMID: 16786907

Year	Number of Results
1949	1
1999	1
2002	2
2003	2
2004	1
2005	1
2006	6
2007	6
2008	7
2009	4
2010	9
2011	13
2012	12
2013	10
2014	19
2015	14
2016	10
2017	6
2018	10
2019	10
2020	12
2021	8
2022	18
2023	7
2024	0

1

Acute decompensated heart failure: the cardiorenal syndrome.

Francis G. Francis G. Cleve Clin J Med. 2006 Jun;73 Suppl 2:S8-13; discussion S30-3. doi: 10.3949/ccjm.73.suppl_2.s8. Cleve Clin J Med. 2006. PMID: 16786907 Free article. Review.

2

Acute decompensated heart failure and the cardiorenal syndrome.

Liang KV, Williams AW, Greene EL, Redfield MM. Liang KV, et al. Crit Care Med. 2008 Jan;36(1 Suppl):S75-88. doi: 10.1097/01.CCM.0000296270.41256.5C. Crit Care Med. 2008. PMID: 18158481 Review.

3

Cardiorenal syndrome in decompensated heart failure.

Tang WH, Mullens W. Tang WH, et al. Heart. 2010 Feb;96(4):255-60. doi: 10.1136/hrt.2009.166256. Epub 2009 Apr 27. Heart. 2010. PMID: 19401280 Review.

4

Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study.

Matsue Y, Suzuki M, Nagahori W, Yoshida K, Onishi Y, Satoh Y, Ono Y, Nishioka T, Noda M, Sugi K, Torii S, Tejima T, Sakurada H, Yamaguchi S, Okishige K, Fujii H, Takahashi A. Matsue Y, et al. Cardiovasc Drugs Ther. 2014 Feb;28(1):73-7. doi: 10.1007/s10557-013-6491-8. Cardiovasc Drugs Ther. 2014. PMID: 24048511 Clinical Trial.

5

Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure.

Kimura K, Momose T, Hasegawa T, Morita T, Misawa T, Motoki H, Izawa A, Ikeda U. Kimura K, et al. J Cardiol. 2016 May;67(5):399-405. doi: 10.1016/j.jjcc.2015.09.020. Epub 2015 Dec 11. J Cardiol. 2016. PMID: 26692119 Free article. Clinical Trial.

6

Addressing the challenges of cardiorenal syndrome.

Geisberg C, Butler J. Geisberg C, et al. Cleve Clin J Med. 2006 May;73(5):485-91. doi: 10.3949/ccjm.73.5.485. Cleve Clin J Med. 2006. PMID: 16708717 Free article. Review.

7

Renal function, diuretic action, and heart failure: a therapeutic conundrum.

Sica D. Sica D. J Card Fail. 2007 Nov;13(9):698-700. doi: 10.1016/j.cardfail.2007.10.001. J Card Fail. 2007. PMID: 17996816 No abstract available.

8

In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.

De Vecchis R, Ciccarelli A, Ariano C, Cioppa C, Giasi A, Pucciarelli A, Cantatrione S. De Vecchis R, et al. Minerva Cardioangiol. 2011 Dec;59(6):543-54. Epub 2011 Feb 18. Minerva Cardioangiol. 2011. PMID: 21330961

9

Targeting the kidney in acute decompensated heart failure: conventional diuretics and renal-acting vasodilators.

Martin FL, Chen HH, Cataliotti A, Burnett JC Jr. Martin FL, et al. Rev Cardiovasc Med. 2008 Winter;9(1):39-45. Rev Cardiovasc Med. 2008. PMID: 18418308 Review.

10

Short and long-term effects of continuous versus intermittent loop diuretics treatment in acute heart failure with renal dysfunction.

Palazzuoli A, Pellegrini M, Franci B, Beltrami M, Ruocco G, Gonnelli S, Angelini GD, Nuti R. Palazzuoli A, et al. Intern Emerg Med. 2015 Feb;10(1):41-9. doi: 10.1007/s11739-014-1112-5. Epub 2014 Aug 3. Intern Emerg Med. 2015. PMID: 25087085 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

166 results

Results by year